menu ☰
menu ˟

Acarbose fails to lower risk for major adverse CV events in CHD

13 Sep 2017
The risk for major adverse cardiovascular events was not reduced in Chinese adults with coronary heart disease treated with acarbose, but the therapy was effective in reducing the incidence of diabetes, according to findings from the Acarbose Cardiov...

Click here to view the full article which appeared in Endocrinology

IPH Logo